1-3 of 3
Guillaume Richard-Carpentier
Close
Sort by
Journal Articles

Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN

Marta B. Davidson, James A. Kennedy, Jose-Mario Capo-Chichi, Yuliang Shi, Wei Xu, Verna Cheung, Andrea Arruda, Aniket Bankar, Guillaume Richard-Carpentier, Steven Chan, Dawn Maze, Mark D. Minden, Aaron D. Schimmer, Andre C. Schuh, Hassan Sibai, Karen Yee, Anne Tierens, Auro Viswabandya, Vikas Gupta
Journal: Blood Advances
Blood Adv (2024) 8 (5): 1281–1294.
https://doi.org/10.1182/bloodadvances.2023011735
Published: 2024
Includes: Supplemental data
Journal Articles

Outcomes of acute lymphoblastic leukemia with KMT2A ( MLL ) rearrangement: the MD Anderson experience

Clinical Trials & Observations
Guillaume Richard-Carpentier, Hagop M. Kantarjian, Guilin Tang, C. Cameron Yin, Joseph D. Khoury, Ghayas C. Issa, Fadi Haddad, Nitin Jain, Farhad Ravandi, Nicholas J. Short, Courtney D. DiNardo, Koichi Takahashi, Marina Y. Konopleva, Naval G. Daver, Tapan Kadia, Guillermo Garcia-Manero, Rebecca Garris, Susan O’Brien, Elias Jabbour
Journal: Blood Advances
Blood Adv (2021) 5 (23): 5415–5419.
https://doi.org/10.1182/bloodadvances.2021004580
Published: 2021
Journal Articles

Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse

Clinical Trials & Observations
Bachar Samra, Joseph D. Khoury, Kiyomi Morita, Farhad Ravandi, Guillaume Richard-Carpentier, Nicholas J. Short, Siba El Hussein, Philip Thompson, Nitin Jain, Hagop Kantarjian, Elias Jabbour
Journal: Blood Advances
Blood Adv (2021) 5 (20): 3913–3918.
https://doi.org/10.1182/bloodadvances.2021004427
Published: 2021
Includes: Supplemental data